Families Challenge DIAN Scientists to Do Even More, Faster
Regulatory and pharma scientists fielded pleas from families with autosomal-dominant Alzheimer’s disease just prior to the AAIC conference.
6383 RESULTS
Sort By:
Regulatory and pharma scientists fielded pleas from families with autosomal-dominant Alzheimer’s disease just prior to the AAIC conference.
100 DIAN Family Members Gather for Their First International Meeting At DIAN Family Meeting, Funding News Caps Talk of Inadequate Services Families Challenge DIAN Scientists to Do Even More, Faster Throughout the five days of the 2015 Alzheimer's Ass
Tiny injuries to capillaries in white matter, and to cells in gray matter, have come to be the focus of new imaging measures being explored in early presymptomatic AD.
At AAIC, new data on three anti-Aβ antibodies reinforced a sense of hope that Aβ immunotherapy may yet work out. Challenges with each antibody notwithstanding, all four leading candidates, including crenezumab, are now in Phase 3.
Polythiophene compounds stabilized prions and prevented them from spreading through the brains of infected mice. Researchers predicted the compounds could work on Aβ and tau, too.
At the right intensity and treatment duration, aerobic exercise can sharpen thinking skills and improve brain function even in cognitively impaired people, say researchers.
Researchers report multiple benefits of aerobic exercise on brain function, including some hints it could slow tau pathology.
Variability still plagues CSF biomarker measurements, but automated systems offer hope of a diagnostic assay.
Research uncovers subtle links between early development problems and some forms of dementia.
Though BACE1 and γ-secretase appear to orchestrate axonal pathfinding, researchers doubt inhibitors or modulators of these proteases would cause side effects in people treated for AD.
Can proteins in the cerebrospinal fluid help tell movement disorders apart and predict who will develop dementia?
The synaptic protein abounds in the cerebrospinal fluid of AD patients and in those in the prodromal phase of the disease.
Prevention trials are testing new protocols for telling potential participants about their heightened risk for dementia, and exploring the psychological effect of such disclosures.
The largest trial yet of ApoE4 carriers is pioneering new protocols with increasing use of technology to reach thousands of potential participants and disclose risk information.
Scanning for amyloid plaques in the brain may help clinicians diagnose and manage patients with a questionable diagnosis of Alzheimer’s.
No filters selected